Evidence map›Paper›PMID 27734205›Full record

Trial reportJournal of gastrointestinal cancer2017

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.

Michael J McNamara, David J Adelstein, Daniela S Allende, Joanna W Bodmann, Denise I Ives, Sudish C Murthy, Daniel Raymond, Siva Raja, Cristina P Rodriguez, Davendra Sohal and 3 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Journal of gastrointestinal cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Michael J McNamaraCleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA. mcnamam@ccf.org.
David J AdelsteinCleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA.
Daniela S AllendeDepartment of Pathology, Cleveland Clinic, 9500 Euclid Avenue, L25, Cleveland, OH, 44195, USA.
Joanna W BodmannCleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA.
Denise I IvesCleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA.
Sudish C MurthyCleveland Clinic, Heart and Vascular Institute, Thoracic and Cardiovascular Surgery, 9500 Euclid Avenue, J4-1, Cleveland, OH, 44195, USA.
Daniel RaymondCleveland Clinic, Heart and Vascular Institute, Thoracic and Cardiovascular Surgery, 9500 Euclid Avenue, J4-1, Cleveland, OH, 44195, USA.
Siva RajaCleveland Clinic, Heart and Vascular Institute, Thoracic and Cardiovascular Surgery, 9500 Euclid Avenue, J4-1, Cleveland, OH, 44195, USA.
Cristina P RodriguezDepartment of Medicine, Division of Medical Oncology, University of Washington, 825 Eastlake Ave E. MS G4-940, Seattle, WA, 98109, USA.
Davendra SohalCleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA.
Kevin L StephansCleveland Clinic, Taussig Cancer Institute, Radiation Oncology, 9500 Euclid Avenue, T28, Cleveland, OH, 44195, USA.
Gregory M M VideticCleveland Clinic, Taussig Cancer Institute, Radiation Oncology, 9500 Euclid Avenue, T28, Cleveland, OH, 44195, USA.
Lisa A RybickiCleveland Clinic, Quantitative Health Sciences, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Cleveland Clinic · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePreoperative therapy is frequently employed in the management of esophageal adenocarcinoma. However, many patients are found to have advanced pathologic stage and have poor outcomes. A prognostic factor which identifies this patient population before surgery would be desirable, as alternative treatment strategies may be warranted.

methodsBetween 2/08 and 1/12, 60 evaluable patients with locally advanced esophageal adenocarcinoma enrolled in single-arm phase II trial of induction chemotherapy, surgery, and post-operative adjuvant chemo-radiotherapy (CRT). A clinical stage of T3, N1, or M1a (AJCC 6th) was required for eligibility. Induction chemotherapy with epirubicin 50 mg/m

resultsPersistent dysphagia was associated with worse distant metastatic control [HR 3.48 (1.43-8.43), p = 0.006], recurrence free survival [HR 3.04 (1.34-6.92), p = 0.008], and overall survival [HR 3.31 (1.43-7.66), p = 0.005]. Persistent dysphagia was associated with more advanced pathologic T descriptor (pT) (p = 0.048) and N descriptor (pN) (p = 0.002), a greater median number of involved lymph nodes (3 v 1, p = 0.003), and greater residual tumor viability (p = 0.05). No patients with persistent dysphagia had pT0-T2 or pN0 disease.

conclusionsPersistent dysphagia after induction chemotherapy is associated with more advanced pathologic stage and inferior outcomes.

Indexed as

AdenocarcinomaAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCisplatinDeglutition DisordersDisease-Free SurvivalEpirubicinEsophageal NeoplasmsFemaleFluorouracilHumansInduction ChemotherapyAntineoplastic AgentsCisplatinEpirubicinFluorouracilOrganoplatinum CompoundsOxaliplatinDysphagiaEsophageal cancerPreoperative chemotherapy

Identifiers

PMID27734205
OpenAlexW2531476362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.